Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADX:JULPHAR vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a Buyback Yield % of 0.00 as of Aug. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #999999 out of 38 companies in the Medical Distribution industry.
Is Gulf Pharmaceutical Industries PSC's Buyback Yield % too high?
Gulf Pharmaceutical Industries PSC's current Buyback Yield % is 0.00. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #999999 out of 38 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #999999 out of 38 companies for Buyback Yield %. This places Gulf Pharmaceutical Industries PSC in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. Gulf Pharmaceutical Industries PSC's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.05, compared to a current price of د.إ1.04 — trading 1% below its estimated fair value. The current Buyback Yield % is 0.00. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current Buyback Yield % is 0.00 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.04 is trading 1% below its estimated GF Value™ of د.إ1.05.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
Buyback Yield %: 0.00
GF Value™: د.إ1.05 vs. price of د.إ1.04 (1% below fair value)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score
Get the complete analysis for ADX:JULPHAR
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
